High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells - Wikidata - awgldk - TriplyDB

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

http://www.wikidata.org/entity/Q33806895

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect T lymphocytes targeting native receptors Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells Immunotherapy: opportunities, risks and future perspectives Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies The role of peptide and DNA vaccines in myeloid leukemia immunotherapy Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.Vaccines targeting cancer stem cells: are they within reach?New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.Recent advances in T-cell immunotherapy for haematological malignancies.Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.Immunophenotypic characterization of CD45RO+ and CD45RA+ T cell subsets in peripheral blood of peripheral T cell lymphoma patients.Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses.Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.What challenges remain in chronic myeloid leukemia research?The progress and current status of immunotherapy in acute myeloid leukemia.Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

P2860

Q26770391-99E5E88B-8AC6-4820-ABF7-ACFE4C66ABFC Q26826830-67F36814-75AC-4263-A49D-DF87984CF0DC Q26853345-501BEC7C-0E7C-40A7-908D-3DB852D66832 Q27313856-4AD0C58E-C3A3-41AC-8022-616EC3519135 Q28486108-B03A2B63-1D5F-4C4C-BFA0-D6958F6D6B0D Q33941012-C1D08C8F-65D2-47FC-946F-3468F2C8A371 Q34018782-F6E2F1AE-F96F-4A86-B775-61FA46A86FB4 Q34608912-A214AB6A-C6FC-4D15-A174-124E69BC96AC Q34862104-B891BBFF-298A-429B-9115-6A4E39706F35 Q34870799-A85C0CB0-2335-4036-880F-65047FFD8932 Q35194860-225F42DD-CDAD-4758-846C-A56B8BC67A16 Q35196739-D560B0F4-AA35-4899-8CBB-97DA657F486C Q35677112-049FBC36-130C-48A6-8DB1-F74F2FA27547 Q36194235-D1480A8B-6E81-4EC0-A248-4FB4A71FC439 Q36322371-BE2AE030-2A2A-425F-AD8D-AB709958280C Q36366557-44AEEF4D-0856-4839-A2B6-769651FF3669 Q36544893-8EC1C277-F075-4EE1-A9E9-6F3AE071CC2B Q36608571-BD9F5C75-3213-4649-A321-20962007BEE2 Q37185223-480C032B-A51B-435D-B0FA-4CE736116FC9 Q37242561-E199292E-4000-4C26-BCE2-ADDE02128072 Q37644842-A99F210E-DB2A-4454-AB7B-3F46D38B24DA Q37939527-5C6E7076-7DEA-4E95-A337-BC8AAE729360 Q38245928-79916769-0855-4003-AEA3-8CC3344BF034 Q38789518-5A336D37-C7F0-4435-8AC9-E0B94321C9CA Q39043196-0AF6ED2B-B69E-4796-9434-8AC99C487CC2 Q39148534-C29CBB4B-B195-435C-987C-602E70B0EB88 Q39160149-66D61C61-9EA4-4628-BB4D-5CA83499AF78 Q39190130-848651C7-5635-42D5-B6AF-9216C8B20A24 Q39379516-902DD3FB-AD05-4F8C-A8B3-9184EDE1CCC4 Q39472050-E96ECED1-A1F9-4BE9-A7EA-9EE6D024615C Q40725673-9C61A576-83E8-45CF-9572-66B3B0332032 Q40987686-943393B5-54A0-4614-BF40-41132F3F7CC3 Q41279759-FAEB1E8F-DE34-4AF4-B471-BEBB1A7189C4 Q42003336-1D19953C-33D1-4AF2-BC4B-FE2A29F79650 Q42540300-135C4D75-7B32-458A-9BE8-E30BCF23D731 Q42935464-E87C5553-9B81-47D0-850A-7ADD8C2C07AE Q47590707-D9026CE5-5BCB-4726-A351-5B5341B72BEE Q54945635-CBC05EA0-B27D-44C5-A1BC-B2BE1ABAD7E4

P2860

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

http://www.wikidata.org/entity/Q33806895

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@ast

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@en

type

label

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@ast

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@en

prefLabel

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@ast

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@en

P1433

Q33806895-8388ED98-B6A2-4F62-93A6-B913C1161807

P1476

Q33806895-B38DFA88-8C0D-4DC6-A4BA-9FECCB166BC6

P2093

Q33806895-3DCDE6A8-AC93-43D1-88BE-067425A82B29

Q33806895-436BDD18-DE2C-484E-BE07-1C4BA449C539

Q33806895-59FA3083-7454-4FC3-99E6-2E78275D2F90

Q33806895-601A0C8E-1BEC-46BB-870E-5C4991AADE23

Q33806895-6622E0A3-8753-4BE7-9899-630187D6053E

Q33806895-8D540A33-1251-479E-B30D-DA6607EC8811

Q33806895-D41AFF7E-E710-46DD-ACEF-E91F501ED9A3

Q33806895-DADD093F-6603-4308-BBEE-30776F44D5A7

Q33806895-EF5489C2-B992-4A0E-9C97-39EF10623574

Q33806895-F1056B1D-6AAB-4A5E-86FA-8D8503417050

P2860

Q33806895-046AB4A2-66E1-4745-A80D-0C7E4D1C2509

Q33806895-0D8BF21D-7BAE-4C02-91AC-3AE7B8D52AA5

Q33806895-138FBEEE-7235-4CD8-92E6-3AC72413BF9C

Q33806895-1C69C913-8AFE-4ED6-9845-231944B0F2E0

Q33806895-28FFF321-9952-4AF8-8EB9-B64240878E40

Q33806895-3587511E-D24B-4B31-A712-FC3449C31D95

Q33806895-374E8851-7524-482A-9C27-47447A80F647

Q33806895-59FE7D76-6E83-4764-94AA-07F6BBF9FC84

Q33806895-5B8761FD-25C4-4565-87E8-932FCFA95FED

Q33806895-5EF0E35F-B74B-45A4-9B27-FB52583CE75B

P304

Q33806895-0A410973-C2C3-46E4-82C5-24323319C8EC

P31

Q33806895-892622CA-C7E6-497D-9860-DC2DE38E4E08

P356

Q33806895-F96E2475-F2ED-4631-8F30-96941EBBC5B6

P407

Q33806895-071BF277-37C1-4254-B574-63A646A220D2

P433

Q33806895-43E73FDE-4C1D-42CC-8990-18B7E0E8DEC7

P478

Q33806895-117C1A7A-2A73-4337-BEE2-ECF4523F1D77

P50

Q33806895-B19AD013-A897-4581-B984-F7652C7639A6

Q33806895-B77EB36B-A3B3-448F-A482-4016DCF054BF

Q33806895-E1DCDBEE-626B-4B5C-BE78-705163685939

P577

Q33806895-981B86F9-4F42-4805-A3E4-B119B6AA43B6

P5875

Q33806895-985120E4-7433-4FF4-8E0A-7E911DD28AAE

P698

Q33806895-26B5F4B0-BE32-4428-A8BB-00A4AE417042

P921

Q33806895-67F933DB-5DAA-4C7C-BB42-373D0CFAB7A5

Q33806895-B90127F7-0B4C-452D-BCF7-9CC97A2B3134

P932

Q33806895-EFC8360B-5DA4-4A85-98BA-53A566B338B1

P356

BLOOD-2010-08-300376

P1433

P1476

High-avidity cytotoxic T lymph ...... c and leukemic-precursor cells

@en

P2093

Ann M Leen

http://www.w3.org/2001/XMLSchema#string

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Helen E Heslop

http://www.w3.org/2001/XMLSchema#string

Jessica Shafer

http://www.w3.org/2001/XMLSchema#string

Luigia Luciano

http://www.w3.org/2001/XMLSchema#string

Malcolm K Brenner

http://www.w3.org/2001/XMLSchema#string

Martha Mims

http://www.w3.org/2001/XMLSchema#string

Santa Errichiello

http://www.w3.org/2001/XMLSchema#string

P2860

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling

PRAME gene expression in childhood acute lymphoblastic leukemia

PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.

Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.

Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.

Gene expression changes associated with progression and response in chronic myeloid leukemia.

Immunotherapy of hematologic malignancy.

P304

3353-3362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-08-300376

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Concetta Quintarelli

Biagio De Angelis

P577

2011-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49795693

http://www.w3.org/2001/XMLSchema#string

P698

21278353

http://www.w3.org/2001/XMLSchema#string

P921

P932

3069675

http://www.w3.org/2001/XMLSchema#string